One in 10 babies is born too soon
With an incidence of one in 10 pregnancies1, preterm birth is considered by many medical experts to be a public health crisis. The emotional, financial, and long-term health implications for preterm babies and their families can be overwhelming. Up until this point, ways to accurately predict the risk of a preterm delivery have been limited, with only a small percentage of high risk patients identified through clinical or demographic risk factors.
![doctor touching pregnant women's belly](https://www.pretrm.com/wp-content/uploads/2021/08/iStock-815494772-1-1380x776.jpg)
Determine your patient’s risk of spontaneous preterm birth, even if she lacks evident risk factors
The PreTRM® Test provides physicians with their patients’ risk for spontaneous premature birth in asymptomatic, singleton pregnancies.⁶ This pivotal information — provided in the form of an individual risk percentage — gives you sufficient time and vital insights to make informed treatment decisions with your patients.
The PreTRM® Test is designed to identify patients at higher risk for spontaneous preterm birth
Accurately identifying women at higher risk for spontaneous preterm delivery is a critical first step to addressing an early delivery’s health impacts. PreTRM Test integration enables you to more accurately identify and manage preterm birth risk for better outcomes.
![](https://www.pretrm.com/wp-content/uploads/2022/06/PreTRM-Updated-Performance-Visual-GRAPH-ONLY-1.png)
The PreTRM test is suitable for 88% of singleton pregnant women4,5
PreTRM® Intended Use:
The PreTRM® Test for Risk Management predicts the risk of spontaneous preterm birth (before 37 weeks) in asymptomatic women (no signs or symptoms of preterm labor, with intact membranes) with a singleton pregnancy.⁶ The PreTRM Test is performed via a single blood draw between 18 and 20 6/7 weeks of gestation (126-146 days). It is not intended for use in women who have a multiple pregnancy, have a known or suspected fetal anomaly, or are on any form of progesterone therapy after the first trimester.
- Women ≥18 years old with a singleton pregnancy
- Not on heparin therapy
- No prior history of preterm birth or shortened cervix
- Asymptomatic for preterm labor
- Not on progesterone therapy after the first trimester
- No known or suspected fetal anomaly
Offer the PreTRM® Test at Your Practice
References
- Osterman, MJK, et al. Births: Final Data for 2020. Division of Vital Statistics, National Center for Health Statistics, U.S. Centers for Disease Control and Prevention. (February 2022). Available at https://www.cdc.gov/nchs/nvss/births.htm
- Iams, JD. Clinical Practice. Prevention of preterm parturition. N Engl J Med. 2014;370:254-61.
- Burchard, J., et al. Better Estimation of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating. J. Clin. Med. 2022, 11, 2885. https:// doi.org/10.3390/jcm11102885
- Petrini JR, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005;105:267-72.
- Hassan SS, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18-31.
- Considerations for use: The PreTRM Test for Risk Management predicts the risk of spontaneous preterm birth (before 37 weeks) in asymptomatic women (no signs or symptoms of preterm labor with intact membranes) ≥18 years old with a singleton pregnancy. The PreTRM Test is performed via a single blood draw between 18wk – 20wk/6d (126 – 146 days) gestation. It is not intended for use in women who have a multiple pregnancy, have a known or suspected fetal anomaly, or are on any form of progesterone therapy after the first trimester. If the PreTRM Test was ordered for a patient outside of intended use for this test, caution should be exercised when interpreting the personalized risk results.